Domestic price of vepotuzumab (POLIVY)

The U.S. Food and Drug Administration (FDA) approved velpotuzumab (POLIVY) along with rituximab products, cyclophosphamide, doxorubicin and prednisone (R-CHP) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and an International Prognostic Index (IPI) score of 2 or higher.

The recommended dose of vepotuzumab is 1.8 mg/kg, used in combination with R-CHP, and administered intravenously every 21 days for a total of 6 cycles. Patients should take antihistamines and antipyretics in advance, and receive prophylactic granulocyte colony-stimulating factor therapy. The efficacy was based on investigator-assessed progression-free survival (PFS). PFS in the vepotuzumab + R-CHP group was statistically significantly longer, with a hazard ratio of 0.73, and no significant difference in complete response rate or overall survival rate.

Vepotolizumab's patent medicine has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around RMB 10,000. The price of the Hong Kong version of 140 mg per box may be around RMB 60,000 (the price may fluctuate due to exchange rates) overseas. The price of the European version of vepotuzumab on the market, Specifications140 mg per box, may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs are basically the same as those of foreign original drugs, and they are expensive. There are currently no generic versions of vepotuzumab on the market.